Kambiz Rahbar
University of Münster
Internal medicineRadiologyUrologyPET-CTPathologyOncologyAdverse effectGlutamate carboxypeptidase IIPositron emission tomographyProstateProstate cancerLymph node177Lu-PSMA-617Nuclear medicineRadionuclide therapyIn patientMembrane antigenCastration resistantCancer researchProportional hazards modelRadioligandMedicine
135Publications
22H-index
2,427Citations
Publications 140
Newest
#1Dirk BeyersdorffH-Index: 13
#2Kambiz RahbarH-Index: 22
Last. Johannes M. WolffH-Index: 3
view all 0 authors...
Background null Numerous diagnostic and therapeutic innovations in the treatment of advanced prostate cancer, both in the hormone-sensitive and in the castration-resistant situation, recently led to a new orientation in the management of this tumor. However, there are potential indications beyond the ones covered by the S3 guideline on early detection, diagnosis and therapy of prostate cancer in clinical care that might be helpful for patients. null Objectives null Since July 2018, an interdisci...
Source
#1Wolfgang RollH-Index: 6
Last. Kambiz RahbarH-Index: 22
view all 9 authors...
177Lutetium PSMA-617 (Lu-PSMA) therapy in patients with metastatic castration resistant prostate cancer (mCRPC) has gained visibility through the ongoing phase III trial. The data on prediction of therapy outcome and survival out of pretherapeutic imaging parameters is still sparse. In this study, the predictive and prognostic value of radiomic features from 68Ga-PSMA-11 PET-MRI are analyzed. In total, 21 patients with mCRPC underwent 68Ga-PSMA-11 PET-MRI before Lu-PSMA therapy. The PET-positive...
Source
#1Marianne PattH-Index: 24
#2Frank M. Bengel (Hochschule Hannover)H-Index: 70
Last. Wolfgang WeberH-Index: 61
view all 11 authors...
Source
#1Konstantin SeitzerH-Index: 1
#2Robert SeifertH-Index: 10
Last. Kambiz RahbarH-Index: 22
view all 7 authors...
Patients suffering from metastatic castration-resistant prostate cancer (mCRPC) have a poor prognosis. As a further treatment option 177Lutetium (Lu) prostate-specific membrane antigen (PSMA) radioligand therapy gained a significant interest of many investigators. Several publications showed great response and prolonged survival with limited adverse events. However, to this point, it still remains unclear which patients benefit the most from 177Lu-PSMA therapy, and how to improve the treatment r...
Source
#1Katharina KesselH-Index: 6
#2Christof BernemannH-Index: 11
Last. Kambiz RahbarH-Index: 22
view all 4 authors...
Metastatic castration-resistant prostate cancer (mCRPC) remains an incurable disease, despite multiple novel treatment options. The role of prostate-specific membrane antigen (PSMA) in the process of mCRPC development has long been underestimated. During the last years, a new understanding of the underlying molecular mechanisms of rising PSMA expression and its association with disease progression has emerged. Accurate understanding of these complex interactions is indispensable for a precise di...
Source
#1Ian Alberts (University of Bern)H-Index: 10
#2Robert Seifert (DKFZ: German Cancer Research Center)
Last. Ali Afshar-Oromieh (University of Bern)H-Index: 37
view all 4 authors...
Prostate-specific membrane antigen-PET/computed tomography (PSMA-PET/CT) is the investigation of choice for imaging prostate cancer. Demonstrating high diagnostic accuracy, PSMA-PET/CT detects disease at very early stages of recurrence, where the chances of a definitive cure may be at their greatest. A number of PSMA-radioligands are in established clinical routine, and there are currently only limited data and no single tracer can clearly be advocated over the others at present. Further clinica...
Source
#1Robert SeifertH-Index: 10
#2Ian AlbertsH-Index: 10
Last. Kambiz RahbarH-Index: 22
view all 4 authors...
Prostate-specific membrane antigen (PSMA) has been the subject of numerous studies within the last 3 decades. PSMA-targeted imaging and therapy have significantly changed the management of patients with prostate cancer in various disease stages, especially in advanced metastasized castration-resistant prostate cancer. Lutetium-177-conjugated PSMA-617 or PSMA-I&T (Lu-PSMA) has shown promising results in multicenter retrospective and monocenter prospective trials. The aim of this review is to prov...
Source
7 CitationsSource
#1Hojjat Ahmadzadehfar (University Hospital Bonn)H-Index: 36
#2Ralf Matern (University Hospital Bonn)H-Index: 1
Last. Kambiz RahbarH-Index: 22
view all 19 authors...
INTRODUCTION Prostate-specific membrane antigen (PSMA)-based radioligand therapy (RLT) showed in a multicentre WARMTH (World Association of Radiopharmaceutical and Molecular Therapy) study that the presence of bone metastases is a negative prognosticator for the survival. The current multicentre retrospective analysis aims to evaluate the response rate to RLT, the overall survival (OS) of patients and the safety of the treatment according to the extent of bone involvement. METHODS The study incl...
2 CitationsSource
Source